{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T08:40:37Z","timestamp":1792658437985,"version":"4.5.0"},"reference-count":83,"publisher":"Oxford University Press (OUP)","issue":"1187","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This systematic narrative review evaluates the efficacy, safety, and future potential of stereotactic body radiation therapy (SBRT) in locally advanced pancreatic cancer (LAPC), particularly for patients unsuitable for surgery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic search of PubMed, Embase, and the Cochrane Library identified English and select non-English studies published between January 2010 and November 2025. Search terms included \u201cpancreatic cancer,\u201d \u201cSBRT,\u201d \u201cLAPC,\u201d \u201cadaptive radiotherapy,\u201d \u201cproton therapy,\u201d \u201ctoxicity,\u201d and \u201coutcomes.\u201d Eligible peer-reviewed studies (clinical trials, cohort studies, systematic reviews; \u226520 patients) reporting local control (LC), overall survival (OS), progression-free survival (PFS), and toxicity were included. Study quality was assessed using the Newcastle-Ottawa Scale and Cochrane Risk of Bias Tool. Owing to heterogeneity, narrative synthesis was performed, supplemented by pooled estimates from recent meta-analyses following PRISMA guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty-five studies were included (25 photon SBRT, 6 protons, 4 carbon-ion). One-year LC ranged 70%-95% (pooled 82%); median OS 13-20\u2009months (pooled 16.8\u2009months). Higher biologically effective doses (BED\u2081\u2080) (&amp;gt;70\u2009Gy) improved LC (HR 0.68). Grade \u22653 acute toxicity was 3%, and late gastrointestinal toxicity 2%. Adaptive MRI-guided SBRT reduced margins (2-3\u2009mm) and toxicity (\u223c40%) while maintaining &amp;gt;90% LC. Proton therapy achieved mOS 19.5\u2009months; carbon-ion therapy reported 95% 1-year LC. Distant progression (60%) predominated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Stereotactic body radiation therapy provides high LC with acceptable toxicity in LAPC. Advanced adaptive and particle techniques enhance precision, but systemic progression remains the main challenge, underscoring the need for multimodal strategies and large randomized trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Advances in knowledge<\/jats:title>\n                    <jats:p>This article summarizes the efficacy of SBRT in LAPC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/bjr\/tqag198","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T13:58:12Z","timestamp":1787579892000},"page":"2249-2260","source":"Crossref","is-referenced-by-count":0,"title":["Stereotactic body radiation therapy for pancreatic cancer: evaluating its efficacy, safety, and future prospects: systematic review"],"prefix":"10.1093","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2040-219X","authenticated-orcid":false,"given":"Biplab","family":"Sarkar","sequence":"first","affiliation":[{"name":"Apollo Multispeciality Hospitals Department of Radiation Oncology, , Kolkata, West Bengal-700054,","place":["India"]},{"name":"GLA University Department of Physics, , Mathura, Uttar Pradesh, 281406,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"key":"2026102204074995400_tqag198-B1","first-page":"15","article-title":"Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries and territories","volume":"75","author":"Bray","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"2026102204074995400_tqag198-B2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.14740\/wjon1166","article-title":"Epidemiology of pancreatic cancer: global trends, etiology and risk factors","volume":"10","author":"Rawla","year":"2019","journal-title":"World J Oncol"},{"key":"2026102204074995400_tqag198-B3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"2026102204074995400_tqag198-B4","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1053\/j.gastro.2020.10.007","article-title":"Worldwide burden of, risk factors for, and trends in pancreatic cancer","volume":"160","author":"Huang","year":"2021","journal-title":"Gastroenterology"},{"key":"2026102204074995400_tqag198-B5","doi-asserted-by":"publisher","first-page":"6127","DOI":"10.1245\/s10434-024-15443-1","article-title":"Radiologic occult metastases in pancreatic cancer: analysis of risk factors and survival outcomes in the age of contemporary neoadjuvant multi-agent chemotherapy","volume":"31","author":"Yee","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"2026102204074995400_tqag198-B6","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0140-6736(16)00141-0","article-title":"Pancreatic cancer","volume":"388","author":"Kamisawa","year":"2016","journal-title":"Lancet"},{"key":"2026102204074995400_tqag198-B7","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"N Engl J Med"},{"key":"2026102204074995400_tqag198-B8","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S0140-6736(16)32409-6","article-title":"Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial","volume":"389","author":"Neoptolemos","year":"2017","journal-title":"Lancet"},{"key":"2026102204074995400_tqag198-B9","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1200\/JCO.22.01134","article-title":"Adjuvant nab-paclitaxel\u2009+\u2009gemcitabine in resected pancreatic ductal adenocarcinoma: results from a randomized, open-label, phase III trial","volume":"41","author":"Tempero","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026102204074995400_tqag198-B10","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.ijrobp.2003.11.004","article-title":"Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer","volume":"58","author":"Koong","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026102204074995400_tqag198-B11","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1200\/JCO.2006.09.7469","article-title":"Stereotactic body radiation therapy in multiple organ sites","volume":"25","author":"Timmerman","year":"2007","journal-title":"J Clin Oncol"},{"key":"2026102204074995400_tqag198-B12","doi-asserted-by":"publisher","first-page":"4078","DOI":"10.1118\/1.3438081","article-title":"Stereotactic body radiation therapy: the report of AAPM Task Group 101","volume":"37","author":"Benedict","year":"2010","journal-title":"Med Phys"},{"key":"2026102204074995400_tqag198-B13","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1002\/1097-0142(19811015)48:8&lt;1705::AID-CNCR2820480803&gt;3.0.CO;2-4","article-title":"Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads+ 5-fluorouracil), and high dose radiation+ 5-fluorouracil. The gastrointestinal tumor study group","volume":"48","author":"Moertel","year":"1981","journal-title":"Cancer"},{"key":"2026102204074995400_tqag198-B14","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.ijrobp.2005.07.002","article-title":"Phase. study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer","volume":"63","author":"Koong","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026102204074995400_tqag198-B15","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1002\/cncr.24059","article-title":"Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas","volume":"115","author":"Chang","year":"2009","journal-title":"Cancer"},{"key":"2026102204074995400_tqag198-B16","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1002\/cncr.29161","article-title":"Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma","volume":"121","author":"Herman","year":"2015","journal-title":"Cancer"},{"key":"2026102204074995400_tqag198-B17","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1259\/0007-1285-62-740-679","article-title":"The linear-quadratic formula and progress in fractionated radiotherapy","volume":"62","author":"Fowler","year":"1989","journal-title":"Br J Radiol"},{"key":"2026102204074995400_tqag198-B18","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.ijrobp.2009.08.046","article-title":"Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer","volume":"78","author":"Mahadevan","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026102204074995400_tqag198-B19","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/1748-717X-8-44","article-title":"Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: a pilot trial demonstrating safety","volume":"8","author":"Gurka","year":"2013","journal-title":"Radiat Oncol"},{"key":"2026102204074995400_tqag198-B20","doi-asserted-by":"publisher","first-page":"110064","DOI":"10.1016\/j.radonc.2023.110064","article-title":"Stereotactic MR-guided on-table adaptive radiation therapy (SMART) for borderline resectable and locally advanced pancreatic cancer: a multi-center, open-label phase 2 study","volume":"191","author":"Chuong","year":"2024","journal-title":"Radiother Oncol"},{"key":"2026102204074995400_tqag198-B21","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.3390\/biomedicines13102390","article-title":"First Spanish experience with stereotactic MR-guided adaptive radiotherapy (SMART) in borderline resectable and locally advanced pancreatic cancer: a prospective study","volume":"13","author":"Gonsalves","year":"2025","journal-title":"Biomedicines"},{"key":"2026102204074995400_tqag198-B22","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ijrobp.2010.05.006","article-title":"Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer","volume":"81","author":"Schellenberg","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026102204074995400_tqag198-B23","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.ijrobp.2023.05.023","article-title":"A multi-institutional phase 2 trial of ablative 5-fraction stereotactic magnetic resonance-guided on-table adaptive radiation therapy for borderline resectable and locally advanced pancreatic cancer","volume":"117","author":"Parikh","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026102204074995400_tqag198-B24","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1001\/jamaoncol.2021.0057","article-title":"Association of ablative radiation therapy with survival among patients with inoperable pancreatic cancer","volume":"7","author":"Reyngold","year":"2021","journal-title":"JAMA Oncol"},{"key":"2026102204074995400_tqag198-B25","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.ijrobp.2016.10.030","article-title":"Stereotactic body radiation therapy for locally advanced pancreatic cancer: a systematic review and pooled analysis of 19 trials","volume":"97","author":"Petrelli","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026102204074995400_tqag198-B26","doi-asserted-by":"publisher","first-page":"979","DOI":"10.3109\/0284186X.2015.1004367","article-title":"Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma","volume":"54","author":"Mellon","year":"2015","journal-title":"Acta Oncol"},{"key":"2026102204074995400_tqag198-B27","doi-asserted-by":"publisher","first-page":"101139","DOI":"10.1016\/j.tranon.2021.101139","article-title":"Survival outcome after stereotactic body radiotherapy for locally advanced and borderline resectable pancreatic cancer: a systematic review and meta-analysis","volume":"14","author":"Liu","year":"2021","journal-title":"Transl Oncol"},{"key":"2026102204074995400_tqag198-B28","doi-asserted-by":"publisher","first-page":"3771","DOI":"10.3390\/cancers15153771","article-title":"Normo- or hypo-fractionated photon or proton radiotherapy in the management of locally advanced unresectable pancreatic cancer: a systematic review","volume":"15","author":"Elkhamisy","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026102204074995400_tqag198-B29","first-page":"101567","article-title":"Clinical outcomes of proton beam therapy for unresectable locally advanced pancreatic cancer: a multi-institutional analysis","volume":"9","author":"Terashima","year":"2024","journal-title":"Adv Radiat Oncol"},{"key":"2026102204074995400_tqag198-B30","article-title":"Prospective phase II clinical trial of carbon ion radiotherapy combined with chemotherapy for locally advanced pancreatic carcinoma","author":"Zhang","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026102204074995400_tqag198-B31","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026102204074995400_tqag198-B32","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.3390\/cancers17182959","article-title":"Radiotherapy for locally advanced pancreatic cancer in the modern era: a systematic review and meta-analysis","volume":"17","author":"Park","year":"2025","journal-title":"Cancers (Basel)"},{"key":"2026102204074995400_tqag198-B33","author":"Wells","year":"2011"},{"key":"2026102204074995400_tqag198-B34","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"2026102204074995400_tqag198-B35","doi-asserted-by":"publisher","first-page":"3486","DOI":"10.1002\/cncr.30706","article-title":"Outcomes for patients with locally advanced pancreatic adenocarcinoma treated with stereotactic body radiation therapy versus conventionally fractionated radiation","volume":"123","author":"Zhong","year":"2017","journal-title":"Cancer"},{"key":"2026102204074995400_tqag198-B36","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1001\/jama.2016.4324","article-title":"Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial","volume":"315","author":"Hammel","year":"2016","journal-title":"JAMA"},{"key":"2026102204074995400_tqag198-B37","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.ijrobp.2013.02.022","article-title":"Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated","volume":"86","author":"Chuong","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026102204074995400_tqag198-B38","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1097\/COC.0000000000000472","article-title":"Dose escalation in stereotactic body radiation therapy for pancreatic cancer: a meta-analysis","volume":"42","author":"Zaorsky","year":"2019","journal-title":"Am J Clin Oncol"},{"key":"2026102204074995400_tqag198-B39","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1245\/s10434-014-4274-5","article-title":"The role of stereotactic body radiation therapy for pancreatic cancer: a single-institution experience","volume":"22","author":"Moningi","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"2026102204074995400_tqag198-B40","doi-asserted-by":"publisher","first-page":"8156","DOI":"10.3748\/wjg.v21.i26.8156","article-title":"Stereotactic body radiotherapy using CyberKnife for locally advanced unresectable and metastatic pancreatic cancer","volume":"21","author":"Su","year":"2015","journal-title":"World J Gastroenterol"},{"key":"2026102204074995400_tqag198-B41","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1177\/1533034616650778","article-title":"Can stereotactic body radiation therapy be a viable and efficient therapeutic option for unresectable locally advanced pancreatic adenocarcinoma? results of a phase 2 study","volume":"16","author":"Comito","year":"2017","journal-title":"Technol Cancer Res Treat"},{"key":"2026102204074995400_tqag198-B42","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1002\/cam4.2100","article-title":"Using adaptive magnetic resonance image-guided radiation therapy for treatment of inoperable pancreatic cancer","volume":"8","author":"Rudra","year":"2019","journal-title":"Cancer Med"},{"key":"2026102204074995400_tqag198-B43","doi-asserted-by":"publisher","first-page":"3554","DOI":"10.1002\/mp.14230","article-title":"Feasibility of real-time motion tracking using cine MRI during MR-guided radiation therapy for abdominal targets","volume":"47","author":"Keiper","year":"2020","journal-title":"Med Phys"},{"key":"2026102204074995400_tqag198-B44","first-page":"100755","article-title":"Improved PTV coverage and OAR sparing with stereotactic MRI-guided adaptive radiotherapy for pancreatic cancer","volume":"54","author":"Lutgendorf-Caucig","year":"2025","journal-title":"Clin Transl Radiat Oncol"},{"key":"2026102204074995400_tqag198-B45","first-page":"101","article-title":"Dose prescription and dosimetry considerations in pancreatic SBRT: HYTEC update","volume":"14","author":"Herman","year":"2024","journal-title":"Pract Radiat Oncol"},{"key":"2026102204074995400_tqag198-B46","doi-asserted-by":"publisher","first-page":"747532","DOI":"10.3389\/fonc.2021.747532","article-title":"Investigate the dosimetric and potential clinical benefits utilizing stereotactic body radiation therapy with simultaneous integrated boost technique for locally advanced pancreatic cancer: a comparison between photon and proton beam therapy","volume":"11","author":"Liu","year":"2021","journal-title":"Front Oncol"},{"key":"2026102204074995400_tqag198-B47","first-page":"450","article-title":"Prospective phase 2 clinical trial of carbon ion radiation therapy for locally advanced pancreatic cancer","volume":"123","author":"Shinoto","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026102204074995400_tqag198-B48","doi-asserted-by":"publisher","first-page":"708884","DOI":"10.3389\/fonc.2021.708884","article-title":"Effectiveness of carbon ion radiation in locally advanced pancreatic cancer","volume":"11","author":"Liermann","year":"2021","journal-title":"Front Oncol"},{"key":"2026102204074995400_tqag198-B49","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1093\/annonc\/mdn281","article-title":"Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD\/SFRO study","volume":"19","author":"Chauffert","year":"2008","journal-title":"Ann Oncol"},{"key":"2026102204074995400_tqag198-B50","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"key":"2026102204074995400_tqag198-B51","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1097\/SLA.0000000000000867","article-title":"Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer","volume":"261","author":"Ferrone","year":"2015","journal-title":"Ann Surg"},{"key":"2026102204074995400_tqag198-B52","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.ijrobp.2015.12.003","article-title":"Focal radiation therapy dose escalation improves overall survival in locally advanced pancreatic cancer patients receiving induction chemotherapy and consolidative chemoradiation","volume":"94","author":"Krishnan","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026102204074995400_tqag198-B53","doi-asserted-by":"publisher","first-page":"167","DOI":"10.15252\/emmm.201606674","article-title":"PD-L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy","volume":"9","author":"Azad","year":"2017","journal-title":"EMBO Mol Med"},{"key":"2026102204074995400_tqag198-B54","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1177\/1756283X16667909","article-title":"Immunotherapy in pancreatic cancer treatment: a new frontier","volume":"10","author":"Thind","year":"2017","journal-title":"Ther Adv Gastroenterol"},{"key":"2026102204074995400_tqag198-B55","doi-asserted-by":"publisher","first-page":"169","DOI":"10.3857\/roj.2022.00479","article-title":"Stereotactic body radiation therapy for pancreatic cancer: a potential ally in the era of immunotherapy?","volume":"40","author":"Park","year":"2022","journal-title":"Radiat Oncol J"},{"key":"2026102204074995400_tqag198-B56","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1158\/2326-6066.CIR-13-0115","article-title":"An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer","volume":"1","author":"Golden","year":"2013","journal-title":"Cancer Immunol Res"},{"key":"2026102204074995400_tqag198-B57","first-page":"50","article-title":"HYTEC guidelines for pancreatic SBRT contours and dosimetry","volume":"14","author":"Benedict","year":"2024","journal-title":"Pract Radiat Oncol"},{"key":"2026102204074995400_tqag198-B58","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.prro.2024.06.004","article-title":"SBRT for pancreatic cancer: a radiosurgery society case-based practical guidelines to challenging cases","volume":"14","author":"Liu","year":"2024","journal-title":"Pract Radiat Oncol"},{"key":"2026102204074995400_tqag198-B59","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/j.1743-7563.2010.01290.x","article-title":"CA19-9 as a predictor of tumor response and survival in patients with advanced pancreatic cancer treated with gemcitabine based chemotherapy","volume":"6","author":"Hammad","year":"2010","journal-title":"Asia Pac J Clin Oncol"},{"key":"2026102204074995400_tqag198-B60","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1200\/JCO.2008.17.7188","article-title":"DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer","volume":"27","author":"Iacobuzio-Donahue","year":"2009","journal-title":"J Clin Oncol"},{"key":"2026102204074995400_tqag198-B61","doi-asserted-by":"publisher","first-page":"101577","DOI":"10.1016\/j.adro.2024.101577","article-title":"Clinical outcomes of proton beam therapy for unresectable locally advanced pancreatic cancer: a single-center retrospective study","volume":"9","author":"Seto","year":"2024","journal-title":"Adv Radiat Oncol"},{"key":"2026102204074995400_tqag198-B62","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ijrobp.2024.12.020","article-title":"Proton beam therapy for pancreatic tumors: a consensus statement from the Particle Therapy Cooperative Group Gastrointestinal Subcommittee","volume":"122","author":"Chhabra","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026102204074995400_tqag198-B63","author":"ClinicalTrials.gov"},{"key":"2026102204074995400_tqag198-B64","author":"ClinicalTrials.gov"},{"key":"2026102204074995400_tqag198-B65","author":"ClinicalTrials.gov"},{"key":"2026102204074995400_tqag198-B66","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1056\/NEJMoa032295","article-title":"A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer","volume":"350","author":"Neoptolemos","year":"2004","journal-title":"N Engl J Med"},{"key":"2026102204074995400_tqag198-B67","doi-asserted-by":"publisher","first-page":"100485","DOI":"10.1016\/j.esmoop.2022.100485","article-title":"Neoadjuvant chemotherapy with or without radiotherapy versus upfront surgery for resectable pancreatic adenocarcinoma: a meta-analysis of randomized clinical trials","volume":"7","author":"Ghanem","year":"2022","journal-title":"ESMO Open"},{"key":"2026102204074995400_tqag198-B68","doi-asserted-by":"publisher","first-page":"100771","DOI":"10.1016\/j.esmoop.2022.100771","article-title":"Does neoadjuvant treatment in resectable pancreatic cancer improve overall survival? A systematic review and meta-analysis of randomized controlled trials","volume":"8","author":"Uson Junior","year":"2023","journal-title":"ESMO Open"},{"key":"2026102204074995400_tqag198-B69","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.ejca.2021.10.023","article-title":"Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: a meta-analysis of randomised controlled trials","volume":"160","author":"van Dam","year":"2022","journal-title":"Eur J Cancer"},{"key":"2026102204074995400_tqag198-B70","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1200\/JCO.21.02233","article-title":"Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the Dutch Randomized PREOPANC trial","volume":"40","author":"Versteijne","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026102204074995400_tqag198-B71","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S2468-1253(22)00348-X","article-title":"Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial","volume":"8","author":"Ghaneh","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026102204074995400_tqag198-B72","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1001\/jamaoncol.2022.2319","article-title":"Efficacy of preoperative mFOLFIRINOX vs mFOLFIRINOX plus hypofractionated radiotherapy for borderline resectable adenocarcinoma of the pancreas: the A021501 phase 2 randomized clinical trial","volume":"8","author":"Katz","year":"2022","journal-title":"JAMA Oncol"},{"key":"2026102204074995400_tqag198-B73","doi-asserted-by":"publisher","first-page":"16022","DOI":"10.1038\/nrdp.2016.22","article-title":"Pancreatic cancer","volume":"2","author":"Kleeff","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"2026102204074995400_tqag198-B74","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1200\/JCO.2016.67.5561","article-title":"Locally advanced, unresectable pancreatic cancer: American society of clinical oncology clinical practice guideline","volume":"34","author":"Balaban","year":"2016","journal-title":"J Clin Oncol"},{"key":"2026102204074995400_tqag198-B75","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.adro.2020.06.011","article-title":"Single-fraction stereotactic body radiation therapy: a paradigm during the coronavirus disease 2019 (COVID-19) pandemic and beyond?","volume":"5","author":"Ng","year":"2020","journal-title":"Adv Radiat Oncol"},{"key":"2026102204074995400_tqag198-B76","doi-asserted-by":"publisher","first-page":"20170563","DOI":"10.1259\/bjr.20170563","article-title":"MRI guided stereotactic radiotherapy for locally advanced pancreatic cancer","volume":"91","author":"Heerkens","year":"2018","journal-title":"Br J Radiol"},{"key":"2026102204074995400_tqag198-B77","doi-asserted-by":"publisher","first-page":"166","DOI":"10.21037\/jgo.2019.03.02","article-title":"Proton beam radiotherapy for pancreas cancer","volume":"11","author":"Rutenberg","year":"2020","journal-title":"J Gastrointest Oncol"},{"key":"2026102204074995400_tqag198-B78","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1016\/j.ijrobp.2009.09.075","article-title":"A dosimetric model of duodenal toxicity after stereotactic body radiotherapy for pancreatic cancer","volume":"78","author":"Murphy","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026102204074995400_tqag198-B79","doi-asserted-by":"publisher","first-page":"111238","DOI":"10.1016\/j.radonc.2025.111238","article-title":"Carbon ion therapy for pancreatic cancer with risk-adapted dose escalation: initial clinical experience","volume":"214","author":"Lai","year":"2026","journal-title":"Radiother Oncol"},{"key":"2026102204074995400_tqag198-B80","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/S1470-2045(15)00222-3","article-title":"Expanding global access to radiotherapy","volume":"16","author":"Atun","year":"2015","journal-title":"Lancet Oncol"},{"key":"2026102204074995400_tqag198-B81","doi-asserted-by":"publisher","first-page":"e7434","DOI":"10.1002\/cam4.7434","article-title":"Escalated-dose radiotherapy for unresected locally advanced pancreatic cancer: patterns of care and survival in the United States","volume":"13","author":"Shi","year":"2024","journal-title":"Cancer Med"},{"key":"2026102204074995400_tqag198-B82","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.pan.2014.10.001","article-title":"Addressing the challenges of pancreatic cancer: future directions for improving outcomes","volume":"15","author":"Hidalgo","year":"2015","journal-title":"Pancreatology"},{"key":"2026102204074995400_tqag198-B83","author":"Gr\u00fctzmann"}],"container-title":["British Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjr\/advance-article-pdf\/doi\/10.1093\/bjr\/tqag198\/70770786\/tqag198.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjr\/article-pdf\/99\/1187\/2249\/70770786\/tqag198.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjr\/article-pdf\/99\/1187\/2249\/70770786\/tqag198.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T08:07:55Z","timestamp":1792656475000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjr\/article\/99\/1187\/2249\/8769513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":83,"journal-issue":{"issue":"1187","published-online":{"date-parts":[[2026,8,24]]},"published-print":{"date-parts":[[2026,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/bjr\/tqag198","relation":{},"ISSN":["0007-1285","1748-880X"],"issn-type":[{"value":"0007-1285","type":"print"},{"value":"1748-880X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,11]]},"published":{"date-parts":[[2026,8,24]]}}}